Use of paramagnetic compounds to measure temperature and pH in vivo

• US 5,753,207 A
• Filed: 08/19/1996
• Issued: 05/19/1998
• Est. Priority Date: 08/21/1995
• Status: Expired due to Fees

• Current Assignee: Beth Israel Deaconess Medical Center, Inc. (Beth Israel Lahey Health, Inc.)
• Original Assignee: Beth Israel Deaconess Medical Center, Inc. (Beth Israel Lahey Health, Inc.)
• Inventors: Clouse, Melvin E., Zuo, Chun S.
• Primary Examiner(s): Hollinden, Gary E.
• Application Number:
  US08/699,496
• Time in Patent Office: 638 Days
• Field of Search: 424/9.36, 424/9.363, 128/653.4, 436/173, 514/184, 514/836, 514/492, 514/502
• US Class Current: 424/9.36
• CPC Class Codes: A61B 5/01 Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue clinical contact thermometers G01K13/20
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: G01R 33/4804 Spatially selective measurement of temperature or pH
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

A method for measuring temperature and/or pH in vivo using paramagnetic compounds, e.g., lanthanide complexes, in conjunction with NMR has been developed. The chemical shift of the nuclear spin in these complexes can then be correlated to temperature. This non-invasive temperature measurement method is particularly useful in monitoring temperature of cancerous tissue during hyperthermic treatment to destroy the cancerous tissue or tumor.

Claims

1. A method for measuring temperature change in a biological tissue, said method comprising:

(a) administering a lanthanide paramagnetic complex to said biological tissue;

(b) subjecting said biological tissue to a magnetic field;

(c) measuring the chemical shift caused by said magnetic field; and

(d) calculating the temperature of said biological tissue from said chemical shift.

wherein said lanthanide paramagnetic complex has a temperature dependence of the ¹ H chemical shift in the range of about 0.15 to about 2.00 ppm/°

C. or said lanthanide paramagnetic complex has a temperature dependence of the ³¹ P chemical shift in the range of about 0.01 to about 4.00 ppm/°

C.

2. The method of claim 1 wherein said lanthanide paramagnetic complex comprises a Thulium lanthanide complex.

3. The method of claim 2 wherein said Thulium lanthanide complex is Thulium(III)-1, 4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis-(methylene phosphate).

4. A methods for reducing cancerous tissue in a subject, said method comprising increasing the temperature in said cancerous tissue in said subject to a selected temperature such that a substantial number of the cancer cells in said cancerous tissue are killed while monitoring the temperature of said cancerous tissue non-invasively to make sure that said selected temperature is maintained in said cancerous tissue, said non-invasive monitoring being carried out by the steps of:

(a) administering a paramagnetic compound to said cancerous tissue;

(b) subjecting said cancerous tissue to a magnetic field;

(c) measuring the chemical shift caused by said magnetic field; and

(d) calculating the temperature of said cancerous tissue from said chemical shift.

5. The method of claim 4 wherein said paramagnetic compound has a temperature dependence of the ¹ H chemical shift in the range of about 0.15 to about 2.00 ppm/°

C.

6. The method of claim 4 wherein said paramagnetic compound has a temperature dependence of the ³¹ P chemical shift in the range of about 0.01 to about 4.00 ppm/°

C.

7. The method of claim 4 wherein said paramagnetic compound comprises a lanthanide complex.

8. The method of claim 7 wherein said lanthanide complex is selected from the group consisting of Thulium lanthanide complexes, Cerium lanthanide complexes, Neodymium lanthanide complexes, Europium lanthanide complexes, Holmium lanthanide complexes, Dysprosium lanthanide complexes, Samarium lanthanide complexes, Erbium lanthanide complexes, Terbium lanthanide complexes, Lutetium lanthanide complexes or Promethium lanthanide complexes.

9. The method of claim 8 wherein said Thulium lanthanide complex is Thulium(III)-1, 4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis-(methylene phosphate).